Fierce Healthcare

MARCH 15, 2023

CMS gives an early look at how it plans to negotiate Part D drug prices in 2026 dmuoio Wed, 03/15/2023 - 17:35

75

75

Fierce Pharma

SEPTEMBER 7, 2023

Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its li | Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies.

116

116

Fierce Pharma

SEPTEMBER 28, 2023

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

105

105

Drug Store News

OCTOBER 12, 2023

The Stockton, Calif.-based based facility will soon provide new career pathways for associates and faster shipping speed for customers, the retailer said.

52

52

STAT

APRIL 16, 2024

It would carve grocers, restaurants, and food warehouses out of a major portion of the FDA’s rules, which are meant to help regulators quickly track down the cause of a foodborne outbreak, and it would delay enforcement of the entire food safety program, slated to begin in 2026, by several years.

FDA 137

FDA 137

Fierce Pharma

MARCH 18, 2024

As bluebird bio works to make the most of three gene therapy launches, cash-flow concerns have been looming over the drugmaker. | The funding should extend bluebird bio's cash runway through the first quarter of 2026 as it advances three gene therapy launches.

114

114

The FDA Law Blog

MARCH 19, 2024

Hyman, Phelps & McNamara, P.C. (HP&M), HP&M), the largest dedicated food and drug law firm in the U.S., is pleased to announce that Director Allyson Mullen has been appointed to the Board of Directors of the Association of Medical Diagnostic Manufacturers (AMDM). This prestigious appointment recognizes Ms.

FDA 59

FDA 59

Drug Store News

OCTOBER 12, 2023

The Stockton, Calif.-based based facility will soon provide new career pathways for associates and faster shipping speed for customers, the retailer said.

52

52

Pharmacy Times

AUGUST 30, 2023

Any new prices established after negotiations will be effective on January 1, 2026.

132

132

STAT

SEPTEMBER 6, 2023

29, Medicare released its highly anticipated list of 10 therapies for which it plans to establish a price by 2026.

127

127

STAT

FEBRUARY 1, 2024

  The negotiated prices won’t take effect until 2026.  The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.    Continue to STAT+ to read the full story…

Pharmaceutical Companies 122

Pharmaceutical Companies Pharmaceutical Companies 122

Fierce Pharma

JANUARY 4, 2024

The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.

115

115

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

110

110

Fierce Pharma

OCTOBER 9, 2023

billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. Zhifei will pay £2.5 billion ($3.05

Vaccines 116

Vaccines 116

Drug Store News

JULY 31, 2023

Sandoz will invest roughly $90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia, by 2026.

97

97

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

122

122

Fierce Healthcare

JULY 14, 2023

It is expected that a new episode-based payment model would be implemented no earlier than 2026, CMMI said. The Center for Medicare and Medicaid Innovation (CMMI) has released a request for information to design a future episode-based payment model. |

98

98

Fierce Pharma

SEPTEMBER 12, 2023

28, 2026. The deal clears “all pending claims” and tees up a potential Dasynoc launch on Sept. 1, 2024, or potentially earlier under certain circumstances. The Sprycel patents in question aren’t due to expire until Sept.

FDA 116

FDA 116

BioPharm

SEPTEMBER 15, 2023

AI’s role in target discovery and manufacturing optimization remained the most chosen application looking three years ahead; however, approximately 43% envision that it will help to build base regulatory submissions.

52

52

Fierce Pharma

OCTOBER 27, 2023

In August, Imbruvica was one of the 10 drugs identified by the CMS that will be subject to price negotiations in 2026. . | Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa. But what about the impact of the Inflation Reduction Act?

111

111

Drug Store News

FEBRUARY 24, 2023

Target plans to spend $100 million to expand its package-sorting network to more than 15 facilities by the end of 2026.

Packaging 98

Packaging 98

PQA

JANUARY 12, 2024

Looking ahead, we are excited to announce dates for the 2024 Leadership Summit, as well as the 2025 and 2026 Annual Meetings. and in 2026, we'll be back in Baltimore. Save the dates for PQA's upcoming major meetings now through 2026! We know you have busy schedules and many meetings to attend throughout the year.

Specialty Pharmacies 64

Specialty Pharmacies Vaccines 64

Fierce Pharma

DECEMBER 14, 2023

Ahead of 2026’s Medicare drug price negotiations, the White House is getting ready to crack down on companies who’ve raised the costs of their medications faster than the rate of inflation.

93

93

STAT

SEPTEMBER 8, 2023

The negotiation, informed by confidential data from manufacturers and analysis by the Centers for Medicare and Medicaid Services, will result in a maximum fair price for each drug, which will be announced Sept. 1, 2024, and will take effect Jan. The Congressional Budget Office has estimated that the negotiations could save Medicare about $3.7

120

120

Pharmaceutical Technology

NOVEMBER 8, 2023

The company’s cash reduction measures are expected to extend its cash runway into 2026.

64

64

STAT

OCTOBER 31, 2023

As Medicare prepares to negotiate prices for its first batch of medicines, an advocacy group argues the agency should factor in controversial patent maneuvers for one drug that will have cost the program nearly $2 billion in additional spending by 2026.

123

123

PharmExec

AUGUST 29, 2023

Lawsuit comes amid announcement of the first 10 drugs eligible for negotiated prices in 2026.

98

98

Pharmaceutical Technology

JULY 20, 2023

The centre is planned for completion in 2026, along with plans to build a $400m biologics manufacturing plant.

74

74

STAT

AUGUST 30, 2023

Department of Health and Human Services named 10 medicines that will be subject to price negotiations for the Medicare program in 2026, a milestone and a point to start appraising the impact of the law , STAT explains. Have a wonderful day, and please do stay in touch. … On Tuesday, the U.S. The landscape here is complicated.

101

101

The Guardian - Pharmaceutical Industry

JANUARY 25, 2024

In a statement on Wednesday, Haleon recalled eight batches of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult, with expiration dates from October 2025 to June 2026. Continue reading.

60

60

STAT

SEPTEMBER 12, 2023

The cuts extend the company’s cash runway into 2026. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle.

133

133

STAT

OCTOBER 11, 2023

The decision meant that data from roughly half of the trial were scrapped, which delayed their plans to seek regulatory approval for the shot until 2026, instead of 2025. Pfizer and Valneva maintained there were no safety issues or adverse events prompting the decision, and instead blamed unspecified problems with the conduct of the study.

Vaccines 108

Vaccines 108

STAT

OCTOBER 3, 2022

1, 2026, opening up JAMA’s or Nature’s website, and being able to read any article for free. Most people who heard the news likely envisioned making a cup of coffee on Jan. Read the rest…

98

98

The Guardian - Pharmaceutical Industry

NOVEMBER 30, 2022

Patients unlikely to receive lecanemab before 2026 and health service does not yet have necessary infrastructure Drug slows cognitive decline in Alzheimer’s patients, study reveals A reorganisation of NHS dementia care is needed to ensure UK patients can receive a groundbreaking drug that slows the progression of Alzheimer’s disease, doctors say.

84

84

STAT

APRIL 19, 2024

Semaglutide will lose patent protection in those countries in 2026, and Biocon is talking to local manufacturers regarding partnerships to ensure supply. The company, which derives most of its revenue from foreign markets such as the U.S.,

101

101

STAT

APRIL 4, 2024

Novo’s patents in China on Ozempic and the related drug Wegovy are set to expire in 2026, according to its annual report. Novo’s Ozempic sales in China more than doubled last year to $694 million, accounting for 5% of global Ozempic sales. Continue to STAT+ to read the full story…

103

103

Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Additionally, Merck has signed patent litigation settlement deals with various generic firms, permitting them to offer generic versions of Januvia and Janumet to the US market in May 2026, or before under specific conditions.

FDA 69

FDA Vaccines 69